# Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

> **NCT07574541** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 52 (estimated)

## Conditions studied

- Adenocarcinoma
- Prostate Cancer
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type

## Interventions

- **BIOLOGICAL:** TriAdeno vaccine
- **DRUG:** N-803

## Key facts

- **NCT ID:** NCT07574541
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2027-06-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07574541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07574541, "Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07574541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*